




The relative strengths and weaknesses of Progenics Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Progenics Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 141% points. The greatest weakness of Progenics Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 423%, being 189% points above the market average of 234%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	72,540	Assets	80,110
Cost of Goods Sold	0	Liabilities	8,309
Intangible Assets	0	Expenses	74,480
Liabilities, Current	6,650	Revenues	84,796
Liabilities, Non-Current	0	Stockholders Equity	71,801
Other Assets	3,532	Net Income	10,381
Other Compr. Net Income	0	Comprehensive Net Income	10,381
Other Expenses	55,654	BaseVar	123,880
Other Liabilities	1,659	ECR before LimitedLiability	378%
Other Net Income	65	Economic Capital Ratio	423%
Other Revenues	84,796		
Property and Equipment	4,038		
Research and Development	578		
Selling, General and Administrative Expense	18,248		